The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt.
Animals
Apoptosis
/ drug effects
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Deoxycytidine
/ analogs & derivatives
Humans
Hyperthermia, Induced
JNK Mitogen-Activated Protein Kinases
/ metabolism
Ki-67 Antigen
/ metabolism
Magnetite Nanoparticles
/ chemistry
Mice, Nude
Pancreatic Neoplasms
/ pathology
Peptides
/ pharmacology
Phenotype
S Phase
/ drug effects
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
Gemcitabine
Gemcitabine (Gem)
Magnetic hyperthermia
Magnetic nanoparticles (MNP)
Mouse model
NucAnt (N6L)
Pancreatic cancer
Journal
Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
28
05
2018
revised:
17
12
2018
accepted:
26
12
2018
pubmed:
4
4
2019
medline:
5
3
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
In this paper we show that conjugation of magnetic nanoparticles (MNPs) with Gemcitabine and/or NucAnt (N6L) fostered their internalization into pancreatic tumor cells and that the coupling procedure did not alter the cytotoxic potential of the drugs. By treating tumor cells (BxPC3 and PANC-1) with the conjugated MNPs and magnetic hyperthermia (43 °C, 60 min), cell death was observed. The two pancreatic tumor cell lines showed different reactions against the combined therapy according to their intrinsic sensitivity against Gemcitabine (cell death, ROS production, ability to activate ERK 1/2 and JNK). Finally, tumors (e.g. 3 mL) could be effectively treated by using almost 4.2 × 10
Identifiants
pubmed: 30940505
pii: S1549-9634(19)30067-X
doi: 10.1016/j.nano.2018.12.019
pii:
doi:
Substances chimiques
Ki-67 Antigen
0
Magnetite Nanoparticles
0
Peptides
0
Deoxycytidine
0W860991D6
JNK Mitogen-Activated Protein Kinases
EC 2.7.11.24
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101983Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.